Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Niran J Amar"'
Autor:
Wilson Mok, Cindy Weinstein, Davis Gates, Tracey Varnell, Neal Jain, Jan H. Vermeulen, Xiaoli Zhang, Niran J. Amar
Publikováno v:
Pediatric Pulmonology. 55:882-889
OBJECTIVES Asthma affects over 6 million children in the United States alone. This study investigated the efficacy and long-term safety of mometasone furoate-formoterol (MF/F) and MF monotherapy in children with asthma. MATERIALS AND METHODS This pha
Autor:
Lorcan P McGarvey, Zhi Jin Xu, Vivek Iyer, James Krainson, James H. Hull, Mark H Gotfried, Jaclyn A Smith, David Muccino, Gary C Steven, Douglas McQuaid, David I. Bernstein, Gregory Daniel Brooks, David Elkayam, Wen-Chi Wu, Selwyn Spangenthal, Mandel R Sher, Jaclyn A. Smith, Yu-Ping Li, John J Condemi, Ellen R Sher, John R Holcomb, W. Carr, Gary N Gross, SM Parker, Gary D Berman, Ratko Djukanovic, Thomas B. Casale, Jason H Friesen, Krishna Sundar, Christopher E. Brightling, Michael Denenberg, Neil Ettinger, S S Birring, Faisal Alfonso Fakih, Bruce M Prenner, Lorcan McGarvey, Niran J Amar, Jonathan Corren, Tim Harrison, Shaila U Gogate, William W. Storms, Alyn H. Morice, Iftikhar Hussain, Leon S Greos, Anthony Montanaro, Anthony P. Ford, James S Good, Eric J Schenkel, Surinder S. Birring, Thomas R Murphy, Michael S Kaplan, William R Lumry, Jonathan Matz, Michael M. Kitt, Mandel Sher, Alan B Goldsobel, Ian D. Pavord
Publikováno v:
Protocol 012 Investigators 2020, ' Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial ', The Lancet Respiratory Medicine . https://doi.org/10.1016/S2213-2600(19)30471-0
BACKGROUND: Gefapixant is a P2X3 receptor antagonist that has shown promise for the treatment of refractory and unexplained chronic cough. The aim of this study was to evaluate the efficacy of gefapixant compared with placebo after 12 weeks of treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bed8062bd34a8ad548083ad97ee59fbd
https://pure.qub.ac.uk/en/publications/gefapixant-a-p2x3-receptor-antagonist-for-the-treatment-of-refractory-or-unexplained-chronic-cough-a-randomised-doubleblind-controlled-parallelgroup-phase-2b-trial(5aa94b05-a819-433a-a265-b0ce6c143476).html
https://pure.qub.ac.uk/en/publications/gefapixant-a-p2x3-receptor-antagonist-for-the-treatment-of-refractory-or-unexplained-chronic-cough-a-randomised-doubleblind-controlled-parallelgroup-phase-2b-trial(5aa94b05-a819-433a-a265-b0ce6c143476).html
Publikováno v:
Pediatric Pulmonology. 52:310-318
SummaryObjectives Mometasone furoate (MF), delivered via dry-powder inhaler (DPI) QD in the evening (PM), is a treatment option for pediatric patients with asthma. We evaluated MF delivered via a metered-dose inhaler (MDI), in children ages 5–11 ye
Autor:
Neal Jain, X. Zhang, Davis Gates, T. Varnell, Niran J. Amar, C. Weinstein, J. Vermeulen, W. Mok
Publikováno v:
Annals of Allergy, Asthma & Immunology. 123:S35
Publikováno v:
Annals of Allergy, Asthma & Immunology. 122:630-638.e3
GSP301 nasal spray is a fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid).To evaluate the efficacy and safety of GSP301 in patients with seasonal allergic rhinitis (SAR).In this double-blind s
Publikováno v:
Journal of Allergy and Clinical Immunology. 143:AB63
Publikováno v:
Annals of Allergy, Asthma & Immunology. 121:S60
Introduction Seasonal allergic rhinitis (SAR) symptoms often impair quality of life (QoL). In two randomized, double-blind phase 3 studies, twice-daily GSP301 nasal spray, a fixed-dose combination of olopatadine hydrochloride/mometasone furoate, sign
Autor:
Robert C. Cartwright, Niran J. Amar, Alan Kivitz, Steven P. Weinstein, Martin L. Throne, Hal M. Hoffman, Yuhwen Soo
Publikováno v:
Clinical Therapeutics. 34:2091-2103
Background Cryopyrin-associated periodic syndromes (CAPS) are rare, inherited autoinflammatory disorders associated with considerable hardship to patients. The interleukin-1 inhibitor rilonacept has been shown to be well-tolerated and effective in pr
Publikováno v:
Allergy and asthma proceedings. 37(5)
Background Breath-actuated inhalers (BAI) have been developed to simplify the delivery of inhaled medication. Objective To evaluate the safety and efficacy of beclomethasone dipropionate hydrofluoroalkane BAI and metered-dose inhaler (MDI) versus pla
Publikováno v:
Pediatric pulmonology. 52(3)
Mometasone furoate (MF), delivered via dry-powder inhaler (DPI) QD in the evening (PM), is a treatment option for pediatric patients with asthma. We evaluated MF delivered via a metered-dose inhaler (MDI), in children ages 5-11 years with persistent